Chicago Trust’s Quest Diagnostics DGX Stock Holding History

Chicago Trust’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,577	Closed	-$216K	–	310
2022 Q1	$216K	Sell	1,577 -26	-2%	-$3.62K	0.05%	310
2021 Q4	$277K	Buy	+1,603	New	+$244K	0.06%	281

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Chicago Trust's DGX Position: Q2 2022 in Review

Chicago Trust sold out of Quest Diagnostics (DGX) in Q2 2022, closing a stake of 1,577 shares — an estimated $216K sold.

Chicago Trust first reported a position in DGX in Q4 2021 and held it in 2 quarters. The position peaked at $277K in Q4 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

Chicago Trust reported no remaining Quest Diagnostics position as of Q2 2022 after selling out during the quarter.
Chicago Trust sold 1,577 Quest Diagnostics shares in Q2 2022, an estimated $216K.
Chicago Trust first reported a position in Quest Diagnostics in Q4 2021 and held it in 2 quarters.
Chicago Trust's Quest Diagnostics position peaked at $277K in Q4 2021.
851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on Chicago Trust's 13F filing for Q2 2022, filed 3 Aug 2022.